Pharmaceuticals, Biotechnology and Life Sciences
DUBLIN–(BUSINESS WIRE)–The “Fintepla (ZX008) – Emerging Insight and Market Forecast – 2030” report has been added to ResearchAndMarkets.com’s offering.
“Fintepla (ZX008)- Emerging Insight and Market Forecast – 2030” the report provides comprehensive…
TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive Officer, will be presenting a busines…
TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive Officer, will be presenting a busines…
TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive Officer, will be presenting a busines…
TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive Officer, will be presenting a busines…
DUBLIN–(BUSINESS WIRE)–The “CardiolRx-100 – Emerging Insights and Market Forecast – 2030” report has been added to ResearchAndMarkets.com’s offering.
CardiolRx-100 is a pure pharmaceutically produced with high concentration cannabidiol formulation. …
DUBLIN–(BUSINESS WIRE)–The “CFZ533 (ISCALIMAB) – Emerging Insight and Market Forecast – 2030” report has been added to ResearchAndMarkets.com’s offering.
CFZ533 (ISCALIMAB) is a fully human antibody that blocks CD40, a co-stimulatory protein involve…
DUBLIN–(BUSINESS WIRE)–The “CFZ533 (ISCALIMAB) – Emerging Insight and Market Forecast – 2030” report has been added to ResearchAndMarkets.com’s offering.
CFZ533 (ISCALIMAB) is a fully human antibody that blocks CD40, a co-stimulatory protein involve…
CULVER CITY, Calif.–(BUSINESS WIRE)–ImmunityBio, Inc. (NASDAQ: IBRX) today announced it has begun trading as a large cap company with approximately 398 million fully diluted shares outstanding following its merger with NantKwest. The combined company…
Adoption of additional technology solutions demonstrates commitment to patients with cancer and other serious diseases
NEW YORK–(BUSINESS WIRE)–Medidata, a Dassault Systèmes company and the global leader in creating end-to-end solutions to support t…